Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08HXG
|
|||
| Former ID |
DIB006326
|
|||
| Drug Name |
PMX-60056
|
|||
| Synonyms |
PMX-150; PMX-60054; PMX-60065; PMX-60077; PMX-60079; PMX-60087; PMX-640; PMX-686; PMX-747; PMX-801; Heparin andlow molecular weight heparin (LMWH) reversing agents, PolyMedix
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coagulation defect [ICD-11: 3B10.0] | Phase 2 | [1] | |
| Company |
PolyMedix Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C56H79N13O12
|
|||
| Canonical SMILES |
COC1=C(C=C(C=C1)NC(=O)C(CCCCN)N)C(=O)NC(CCCCN)C(=O)NC2=CC(=C(C=C2)OC)C(=O)NC(CCCCN)C(=O)NC3=CC(=C(C=C3)OC)C(=O)NC(CCCCN)C(=O)NC4=CC(=C(C=C4)OC)C(=O)N
|
|||
| InChI |
1S/C56H79N13O12/c1-78-45-21-17-33(29-37(45)49(62)70)64-54(75)42(14-6-10-26-58)67-51(72)39-31-35(19-23-47(39)80-3)66-56(77)44(16-8-12-28-60)69-52(73)40-32-36(20-24-48(40)81-4)65-55(76)43(15-7-11-27-59)68-50(71)38-30-34(18-22-46(38)79-2)63-53(74)41(61)13-5-9-25-57/h17-24,29-32,41-44H,5-16,25-28,57-61H2,1-4H3,(H2,62,70)(H,63,74)(H,64,75)(H,65,76)(H,66,77)(H,67,72)(H,68,71)(H,69,73)/t41-,42-,43-,44-/m0/s1
|
|||
| InChIKey |
PWFIFNGOPQUNIT-ITMZJIMRSA-N
|
|||
| CAS Number |
CAS 872454-31-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Antithrombin-III (ATIII) | Target Info | Antagonist | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Panther Pathway | Blood coagulation | |||
| Pathway Interaction Database | Glypican 1 network | |||
| Reactome | Intrinsic Pathway of Fibrin Clot Formation | |||
| Common Pathway of Fibrin Clot Formation | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01312935) Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI). U.S. National Institutes of Health. | |||
| REF 2 | Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Correction in: Chest. 2013 August; 144(2): 721. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.